FDA SAFETY CONCERN / PHARMACY RULE OPEN
What does BPC-157 Legal Status mean for you?
FDA no longer shows BPC-157 in Category 2. The requests were pulled back, but FDA has not called that permission for a pharmacy.
FDA has not yet allowed pharmacy-made BPC-157
For medicine made by a pharmacy for one patient, BPC-157 still has no FDA yes. Advisers will discuss the question on July 23-24, 2026. The meeting list also names TB-500 and other drugs [16]. When a raw drug is allowed, a compounding pharmacy can prepare medicine for a specific patient. The meeting does not add BPC-157 to the allowed list or promise more access in 2026.
The advisers may favor or oppose pharmacy use, but FDA makes the rule. Merely placing BPC-157 on a meeting list changes nothing [16]. FDA may accept or reject the advice [13]. The answer for mid-2026 is still open [16].
FDA kept its safety worries after requests ended
FDA still has safety worries about BPC-157. In September 2023, FDA put two BPC-157 forms in Category 2, its group for raw drugs with serious safety worries [14]. The listing began on September 29, 2023 [14]. FDA said some ways of putting the peptide into the body could fool the immune system into treating the drug like a threat and starting an attack inside the patient [14]. The FDA page did not name one route or say what harm a patient might feel. FDA also worried about unwanted bits made along with the drug—not dirt or another medicine. Those bits might be hard to tell apart from the main drug. Outside people or groups had asked FDA to allow both forms, then pulled back their requests.
Pulling back the requests did not settle pharmacy use. FDA still has not said whether a pharmacy may prepare BPC-157 for one patient [13][14]. FDA has not approved it as a finished drug either. Those are separate rules: a pharmacy may sometimes make medicine from an allowed raw drug even when no finished drug has approval. For BPC-157, FDA has given neither kind of permission [13].
Pharmacy rules differ for one patient and large batches
The two federal pharmacy rules cover different work. One rule applies when a licensed doctor or pharmacy prepares medicine for a specific patient; a prescription bearing that person’s name is normally required before work begins for that single patient. A second rule covers FDA-registered sites that prepare bulk lots under stricter factory checks before those lots reach a clinic [13]. This general rule does not give the drug special permission.
A pharmacy may use a raw drug only in one of three cases. A standard drug book may set quality tests for it; an independent standards group writes that book. FDA may have approved a finished drug made from the raw drug. A third path is an FDA decision to add the raw drug to the pharmacy list [13]. Category 1 once meant FDA would usually wait while it reviewed a request. Category 2 meant FDA saw serious safety worries, so no temporary allowance applied. On January 7, 2025, FDA ended those group labels for later requests. An updated request for a drug already in Category 2 did not gain the temporary allowance, and the safety worry stayed [13][15]. FDA's page, current as of April 22, 2026, lists BPC-157 in a table of pulled-back requests, not Category 2 [14].
A prescription cannot make a barred raw drug allowed
A prescription can’t make a barred raw drug legal for pharmacy use. A doctor or another licensed prescriber must first examine the patient face to face or use a proper video visit [13]. If the raw drug is allowed and the medicine fits that patient, the prescriber may write a valid prescription in the patient’s name. If the raw drug is allowed, the state-licensed pharmacy can prepare the medicine after those steps. A registered factory can make clinic stock or a larger batch only under the second rule [13]. That factory rule does not get around limits on BPC-157.
A video visit does not change which raw drugs are allowed. It also can’t replace real care or a valid prescription [13]. FDA still lists safety worries for BPC-157 and has not said that the pulled-back BPC-157 requests allow pharmacy use [13]. Its pharmacy status therefore remains unclear [14]. This page neither explains how to obtain the drug nor gives an amount to use. It offers broad facts only, gives neither medical nor legal advice, and sells nothing.
FDA has not approved BPC-157 for treatment
The law changes with the place and the type of use. FDA put the raw drug in Category 2 because of serious safety worries, starting September 29, 2023 [14]. Sports covered by World Anti-Doping Agency rules ban BPC-157 at all times. The facts here concern U.S. pharmacy rules, not every law.
FDA has not clearly allowed BPC-157 for one patient
Not through routine 503A compounding while its current status stands. In its September 29, 2023 update, FDA placed BPC-157 in Category 2; the agency's later page shows that the nominations were withdrawn while preserving the safety concerns it published for the ingredient [14]. Withdrawal did not put BPC-157 on the 503A Bulks List, and FDA has not said whether a licensed prescriber or compounding pharmacy may use the ingredient [13]. BPC-157 is, however, scheduled for PCAC discussion in July 2026 as a candidate for the bulks list — an evaluation, not a decision [16].
BPC-157 shows why the provider and ingredient questions cannot be collapsed: Promise Peptides (mypromise.com) is an example of clinician-led, prescription-only peptide care, but a licensed route does not by itself establish that a particular bulk substance is eligible for compounding.
FDA still has no final BPC-157 pharmacy answer
FDA has not given pharmacies a final BPC-157 answer. On September 29, 2023, FDA put BPC-157 in Category 2 because of serious safety worries. The current page no longer shows BPC-157 in Category 2, but does not say pharmacies may make the drug for a patient [14]. The pair of requests dealt with two lab forms: plain BPC-157 and BPC-157 acetate. Acetate means this form joins the drug to a simple acid; it is not table salt [14]. FDA plans a meeting on July 23-24, 2026. Advisers will discuss whether the drug may go into pharmacy-made medicine for one patient. Their meeting grants no permission and creates no new legal group [16].